ZEALAND PHARMA A/S-ADR logo

ZEAL

ZEALAND PHARMA A/S-ADR

$17.59

Earnings Summary

Revenue
$77.62Mn
Net Profits
$-26.33Mn
Net Profit Margins
-33.92%

Highlights

Revenue:

ZEALAND PHARMA A/S-ADR’s revenue jumped 1091.94% since last year same period to $77.62Mn in the Q1 2017. On a quarterly growth basis, ZEALAND PHARMA A/S-ADR has generated -57% fall in its revenue since last 3-months.

Net Profits:

ZEALAND PHARMA A/S-ADR’s net profit jumped 63.83% since last year same period to $-26.33Mn in the Q1 2017. On a quarterly growth basis, ZEALAND PHARMA A/S-ADR has generated -149.92% fall in its net profits since last 3-months.

Net Profit Margins:

ZEALAND PHARMA A/S-ADR’s net profit margin jumped 96.97% since last year same period to -33.92% in the Q1 2017. On a quarterly growth basis, ZEALAND PHARMA A/S-ADR has generated -216.08% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the ZEALAND PHARMA A/S-ADR post its latest quarter earnings

EPS Estimate Current Quarter
-6.61
EPS Estimate Current Year
-6.61

Highlights

EPS Estimate Current Quarter:

ZEALAND PHARMA A/S-ADR’s earning per share (EPS) estimates for the current quarter stand at -6.61 - a -3.44% fall from last quarter’s estimates.

EPS Estimate Current Year:

ZEALAND PHARMA A/S-ADR’s earning per share (EPS) estimates for the current year stand at -6.61.

Key Ratios

Key ratios of the ZEALAND PHARMA A/S-ADR post its Q1 2022 earnings

Earning Per Share (EPS)
-5.16
Return on Assets (ROA)
-0.34
Return on Equity (ROE)
-0.94

Highlights

Earning Per Share (EPS):

ZEALAND PHARMA A/S-ADR’s earning per share (EPS) jumped 10.73% since last year same period to -5.16 in the Q1 2022. This indicates that the ZEALAND PHARMA A/S-ADR has generated 10.73% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. ZEALAND PHARMA A/S-ADR’s return on assets (ROA) stands at -0.34.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. ZEALAND PHARMA A/S-ADR’s return on equity (ROE) stands at -0.94.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-03-31
-6.61
-5.16
21.94%

Company Information

Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.

Organisation
ZEALAND PHARMA A/S-ADR
CEO
Emmanuel Dulac

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*